Is Septerna Inc (SEPN) a Buy, Sell, or Hold?
NASDAQ : SEPN
Septerna Inc
$31.56 USD
-$2.51 (-7.37%)
- Volume
- 414.07K
- Average Volume
- 422.39K
- Market Capitalization
- $1.42B
- P/E Ratio
- -38.96
- Dividend Yield
- 0.00%
- Price Target
- $45.00
- Year High
- $38.04
- Year Low
- $10.62
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.71
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jeffrey T. Finer |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | SEPN |
| CUSIP | 81734D104 |
| CIK | 0001984086 |
| Web | https://septerna.com |
| Phone | 650 338 3533 |
| Currency | USD |
| Employees | 130 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.06 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.71 |
| Quick Ratio | 4.71 |
| Cash Ratio | 0.92 |
Sales & Book Value
| Annual Sales | $45.95M |
| Price / Sales | 19.69 |
| Cash Flow | 2.39 |
| Price / Cash Flow | 13.30 |
| Price / Book | 3.73 |
Price Target and Rating
| Average Stock Price Forecast | $45.00 |
| High Stock Price Forecast | $60.00 |
| Low Stock Price Forecast | $35.00 |
| Forecast Upside/Downside | -29.87% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.1 |
| Trailing P/E Ratio | -38.96 |
| PEG Ratio | -0.42 |
| P/E Growth | -0.42 |
| Net Income | -$48.88M |
| Net Margin | -49.88% |
| Pretax Margin | -49.40% |
| Return on Equity | -9.44% |
| Return on Assets | -6.33% |
Financials Score
| AltmanZ Score | 4.81 |
| Piotroski Score | 3.00 |
| Working Capital | 289.89M |
| Total Assets | 569.69M |
| Ebit | -53.75M |
| Market Cap | 1.53B |
| Total Liabilities | 191.23M |
Poll Results
About Septerna Inc (NASDAQ:SEPN) Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk ... to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
2026-07-05 09:35:01
Samira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355,000. The transaction reduced direct Common Stock holdings by 93.7%, leaving 793 shares directly owned post-sale.
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
2026-06-29 23:05:01
15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share. This transaction impacted 13.46% of Long's direct Common Stock holdings, reducing his position to 96,412 shares.
2026-06-08 08:00:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Society's Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago. The presentation will highlight the pharmacologic profile of SEP-479, a potent, sel.
Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
2026-05-13 00:20:49
Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
2026-05-11 18:25:23
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.49 per share a year ago.
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
2026-05-11 16:01:00
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026
Septerna to Present at Bank of America Securities Health Care Conference
2026-05-05 08:00:00
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D.
Frequently Asked Questions
-
What is the current Septerna Inc (SEPN) stock price?
-
Septerna Inc(NASDAQ:SEPN) stock price is $31.56 in the last trading session. During the trading session, SEPN stock reached the peak price of $38.04 while $10.616 was the lowest point it dropped to. The percentage change in SEPN stock occurred in the recent session was --7.37% while the dollar amount for the price change in SEPN stock was -$2.51.
-
SEPN's industry and sector of operation?
-
The NASDAQ listed SEPN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SEPN?
-
Mark A. Wilson | Chief Legal Officer
George Xu | Senior Director of Corporate Development & Portfolio Strategy
Samira Shaikhly | Chief People Officer
Arthur Christopoulos BPHARM | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board
Robert J. Lefkowitz | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board -
How many employees does SEPN have?
-
Number of SEPN employees currently stands at 130. SEPN operates from 250 East Grand Avenue, South San Francisco, CA 94080, US.
-
Link for SEPN official website?
-
Official Website of SEPN is: https://septerna.com
-
How do I contact SEPN?
-
SEPN could be contacted at phone #650 338 3533 and can also be accessed through its website. SEPN operates from 250 East Grand Avenue, South San Francisco, CA 94080, US.
-
How many shares of SEPN are traded daily?
-
The average number of SEPN shares traded daily for last 3 months was 422.39K.
-
What is the market cap of SEPN currently?
-
The market value of SEPN currently stands at $1.42B with its latest stock price at $31.56